Four Reasons You Should Sign Up To See The Agenda
- A review of the latest decisions regarding the SPC waiver and its impact upon your generic and innovator life science exclusivity strategy.
- Discover the intersection between regulatory and IP law with industry-led sessions on: clinical trials, data exclusivity, a Tecfidera case law review and the Pharmaceutical Strategy for Europe.
- Understand the requirements for patentability within the life sciences industry with panel sessions on patent quality, G2/21, enablement and the PTAB.
- Discuss the ways in which the UPC is impacting your life science strategy with an industry-led session and judges panel.
After a huge meeting in 2023, the Life Sciences Strategy Summit on IP & Exclusivity is returning to Munich again to review the latest Regulatory Exclusivity Strategies and legal challenges for pharmaceutical, biotech & medical device companies.
We're currently working on our 2024 agenda! Fill out this short form to register your interest and be the first to recieve the latest version when its released.
From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick above.
Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].
User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].
For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.
By clicking submit below, you consent to allow Kisaco Research to store and process the personal information submitted above to provide you the content requested.